The P-IIb trial evaluating MCO-010 (IVT) vs PBO in 27 patients showed vision function improvements after treatment with MCO-010 & were consistent with prior studies with a favorable safety profile
88.9% vs 44.4% achieved a ≥2 luminance level improvement in MLYMT or MLSDT @12mos., 7 out of 18 improved by -0.3 LogMAR or more in BCVA vs 1 out of 9 in PBO, visual acuity gains were observed
No serious or sev. ocular or systemic AEs were reported, 1 SAE in PBO treated patient with a comparable incidence of TEAEs across study arms & the (RESTORE) results are expected to present at upcoming medical conferences. MCO-010, an ambient-light activatable MCO optogenetic therapy for vision restoration has received ODD & FTD from the US FDA
Ref: PRNewswire | Image: Nanoscope Therapeutics
Related News:- Janssen Presents P-I/II (MGT009) and P-I Study Results of Two Gene Therapy Programs for X-Linked Retinitis Pigmentosa and Dry AMD at AAO 2022
